Lower prognostic nutritional index is associated with poorer survival in patients receiving ımmune-checkpoint ınhibitors
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Future Medicine
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim: Blood-based biomarkers like prognostic nutritional index (PNI) are readily available biomarkers for immunotherapy efficacy, although the data are limited. So, we aimed to evaluate the association between PNI and overall survival (OS) in immunotherapy-treated patients. Materials & methods: For this retrospective cohort study, data of 150 immunotherapy-treated advanced cancer patients were evaluated. The association between clinical factors and OS was evaluated with multivariate Cox-regression analyses. Results: After a median follow-up of 8.5 months, 94 patients died. The median OS was 11.07 months. The low PNI (hazard ratio [HR]: 2.065; p = 0.001), high lactate dehydrogenase (HR: 2.515; p = 0.001) and poor Eastern Cooperative Oncology Group (ECOG) status (HR: 2.164; p = 0.009) was associated with poorer OS in multivariate analyses. Conclusion: In our experience, survival with immunotherapy was impaired in patients with lower PNI and higher lactate dehydrogenase levels and poorer ECOG status.
Açıklama
Anahtar Kelimeler
ECOG, LDH, Biomarkers, Immunotherapy, Prognostic Nutritional Index
Kaynak
Biomarkers in Medicine
WoS Q Değeri
Q3
Scopus Q Değeri
N/A
Cilt
Sayı
Künye
Guven, D. C., Aktepe, O. H., Taban, H., Aktas, B. Y., Guner, G., Yildirim, H. C., Sahin, T. K., Aksun, M. S., Dizdar, O., Aksoy, S., Erman, M., Yalcin, S., & Kilickap, S. (2021). Lower prognostic nutritional index is associated with poorer survival in patients receiving ımmune-checkpoint ınhibitors. Biomarkers in medicine, 10.2217/bmm-2020-0674. Advance online publication. https://doi.org/10.2217/bmm-2020-0674
